Guselkumab (Tremfya)

Canada’s Drug Agency (CDA-AMC) recommends that Tremfya be reimbursed by public drug plans for the treatment of adult patients with moderately to severely active Crohn disease if certain conditions are met. Tremfya should only be covered according to the reimbursement criteria used by public drug plans for other advanced therapies for the treatment of adult patients with moderately to severely active Crohn disease. Tremfya should only be reimbursed if the cost of Tremfya is reduced so that it does not cost the drug programs more than the least costly available advanced therapy that is reimbursed for the treatment of moderately to severely active Crohn disease.